The SLFN12 biomarker may have clinical significance as evidenced by its decreased susceptibility to other chemotherapies, like gemcitabine [43] and cisplatin [44], which are occasionally included in salvage or combination regimens for gliomas. This evidence concerns the gene SLFN12 and glioma.